HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
Pediatric Hemostatic Disorders
Assiut Universityprotein_peptideActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Pediatric Hemostatic Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oricar-017 OriCell Therapeutics Co., Ltd. | Phase 1 | CC |
Kln-1010 Kelonia Therapeutics, Inc. | Phase 1 | CC |
Cynk-001 Celularity Incorporated | Phase 1 | D |
Tranexamic Acid Assiut University | D |
Same molecule, other indications
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →